Program Offering and Eligibility

The HEMLIBRA Co-pay Program may help eligible commercially insured patients who have been prescribed HEMLIBRA with their medicine co-pays.

Program offering

Eligible commercially insured patients can save $15,000 per year in medicine costs. They pay as little as $5 per co-pay.

Patients may owe more than $5 depending on how the health insurance plan applies manufacturer co-pay assistance to out-of-pocket costs.


Patients are eligible if they:
  • Have been prescribed HEMLIBRA for an FDA-approved indication
  • Are 18 years of age or older, or have a legal guardian 18 years of age or older to manage the program
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance marketplaces
  • Do not receive support from the Genentech Patient Foundation or any other independent co-pay assistance foundations for HEMLIBRA
  • Are not a government beneficiary and/or participant in a federal or state-funded health insurance program (eg, Medicare, Medicare Advantage, Medigap, Medicaid, VA, DoD or TRICARE)
  • Do not reside in a state where the program is prohibited


If a patient is not eligible for the HEMLIBRA Co-pay Program, there may be other options for co-pay assistance. Call (866) HEMLIBRA (866-436-5427) or visit to learn more.

Indication and Important Safety Information



HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.

Important Safety Information

Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.

Warnings and Precautions

  • Laboratory coagulation test interference: HEMLIBRA interferes with activated clotting time (ACT); activated partial thromboplastin time (aPTT); and coagulation laboratory tests based on aPTT, including one-stage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC-R); and Bethesda assays (clotting-based) for factor VIII (FVIII) inhibitor titers. Intrinsic pathway clotting-based laboratory tests should not be used

Most Common Adverse Reactions

The most common adverse reactions (incidence rate ≥ 10%) were injection site reactions and headache, and arthralgia.

You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information for additional Important Safety Information, including Boxed WARNING.